OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press5110.17650/1818-8346-2012-7-3-30-37HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯPredictive value of initial involvement and early response assessment using positron‑emission tomography with 18F‑FLT in patients with non‑Hodgkin lymphomaПрогностическое значение оценки инициального поражения и раннего ответа на терапию при помощи позитронно‑эмиссионной томографии с 18F‑ФЛТ у пациентов с неходжкинскими лимфомамиLikarYu. N.ЛикарьЮ. Н.
Russian Federation
likar2007@gmail.comDubrovinM. M.ДубровинМ. М.
Russian Federation
Dmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia Memorial Sloan‑Kettering Cancer CenterФГБУ «Федеральный научно‑клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России Memorial Sloan‑Kettering Cancer Centerru2208201220127330372207201422072014Received:22072014Accepted:22072014Published:220820122012https://oncohematology.abvpress.ru/ongm/article/view/51

The monitoring of treatment efficacy in patients with diffuse large B‑cell lymphoma (DLBCL) is generally performed by common computed tomography (CT). However, CT cannot distinguish between a real and residual tissue mass and in addition cannot be very useful in assessment of early response. 18F‑FDG Positron‑emission tomography (PET) has high prognostic implications at treatment completion but is limited as an early predictor. We present the results of a retrospective study where we have evaluated predictive value of initial and interim‑PET(I‑PET) with 18F‑FLT on clinical outcome.

Methods. 39 patients were evaluated retrospectively with 18F‑FLT PET before treatment and interim 18F‑FLT PET after 1 cycles of chemotherapy. PET was performed 40−60 minutes after injection of 270−340 MBq of 18F‑FLT. Maximum standardized uptake values (SUVmax ) were calculated on a lesion. Response was assessed according to protocol during and in the end of therapy.

Results. All lymphoma lesions identified by a reference method (18F‑FDG PET/CT or CT) showed increased focal tracer uptake of 18F‑FLT. Initial mean SUVmax was significantly higher in patients who showed progressive disease and partial response (SUVmax = 9.5 ± 3.2) than inpatients who achieved complete response (SUVmax = 6.3 ± 1.6) (p = 0.018). PFS for positive and negative patients after interim 18F‑FLT PET was 85.1 % and 35.7 %, respectively (р < 0.05).

Conclusion. High initial 18F‑FLT uptake is a negative treatment response predictor in patients with DLBCL. Positive I‑PET with 18F‑FLT is a negative PFS predictor compare to patients with negative I‑PET.

PET18F‑FDG18F‑FLTdiffuse large B‑cell lymphomaПЭТ18F‑ФДГ18F‑ФЛТдиффузная В‑клеточная крупноклеточная лимфома1. Coiffier B., Lepage E., Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‑B‑cell lymphoma. N Engl J Med 2002;346:235−42.Coiffier B., Lepage E., Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‑B‑cell lymphoma. N Engl J Med 2002;346:235−42.2. Pfreundschuh M., Trumper L., Osterborg A. et al. CHOP‑like chemotherapy plus rituximab versus CHOP‑like chemotherapy alone in young patients with good-prognosis diffuse large‑B-cell lymphoma: a randomised controlled trial by Group. Lancet Oncol 2006;7:379−91.Pfreundschuh M., Trumper L., Osterborg A. et al. CHOP‑like chemotherapy plus rituximab versus CHOP‑like chemotherapy alone in young patients with good-prognosis diffuse large‑B-cell lymphoma: a randomised controlled trial by Group. Lancet Oncol 2006;7:379−91.3. Gisselbrecht C., Glass B., Mounier N. et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184−90.Gisselbrecht C., Glass B., Mounier N. et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184−90.4. A predictive model for aggressive non‑Hodgkin's lymphoma. The International Non‑Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987−94.A predictive model for aggressive non‑Hodgkin's lymphoma. The International Non‑Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987−94.5. Juweid M.E., Stroobants S., Hoekstra O.S. et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571−8.Juweid M.E., Stroobants S., Hoekstra O.S. et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571−8.6. Cheson B.D., Pfistner B., Juweid M.E. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579−86.Cheson B.D., Pfistner B., Juweid M.E. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579−86.7. Cheson B.D. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844−54.Cheson B.D. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844−54.8. Hutchings M., Barrington S.F. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009;50 Suppl 1: 21S–30S.Hutchings M., Barrington S.F. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009;50 Suppl 1: 21S–30S.9. Jerusalem G., Beguin Y., Fassotte M.F. et al. Persistent tumor 18F‑FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non‑Hodgkin's lymphoma. Haematologica 2000;85:613−8.Jerusalem G., Beguin Y., Fassotte M.F. et al. Persistent tumor 18F‑FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non‑Hodgkin's lymphoma. Haematologica 2000;85:613−8.10. Spaepen K., Stroobants S., Dupont P. et al. Early restaging positron emission tomography with (18)F‑fluorodeoxyglucose predicts outcome in patients with aggressive non‑Hodgkin's lymphoma. Ann Oncol 2002;13: 1356−63.Spaepen K., Stroobants S., Dupont P. et al. Early restaging positron emission tomography with (18)F‑fluorodeoxyglucose predicts outcome in patients with aggressive non‑Hodgkin's lymphoma. Ann Oncol 2002;13: 1356−63.11. Itti E., Lin C., Dupuis J. et al. Prognostic value of interim 18F‑FDG PET in patients with diffuse large B‑cell lymphoma: SUV‑based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527−33.Itti E., Lin C., Dupuis J. et al. Prognostic value of interim 18F‑FDG PET in patients with diffuse large B‑cell lymphoma: SUV‑based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527−33.12. Haioun C., Itti E., Rahmouni A. et al. [18F]fluoro-2‑deoxy-D‑glucose positron emission tomography (FDG‑PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376−81.Haioun C., Itti E., Rahmouni A. et al. [18F]fluoro-2‑deoxy-D‑glucose positron emission tomography (FDG‑PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376−81.13. Moskowitz C.H., Schoder H., Teruya‑Feldstein J. et al. Risk‑adapted dose‑dense mmunochemotherapy determined by interim FDG‑PET in Advanced-stage diffuse large B‑cell lymphoma. J Clin Oncol 2010; 28:1896−903.Moskowitz C.H., Schoder H., Teruya‑Feldstein J. et al. Risk‑adapted dose‑dense mmunochemotherapy determined by interim FDG‑PET in Advanced-stage diffuse large B‑cell lymphoma. J Clin Oncol 2010; 28:1896−903.14. Shields A.F., Grierson J.R., Dohmen B.M. et al. Imaging proliferation in vivo with [F18]FLT and positron emission tomography. Nat Med 1998;4:1334−6.Shields A.F., Grierson J.R., Dohmen B.M. et al. Imaging proliferation in vivo with [F18]FLT and positron emission tomography. Nat Med 1998;4:1334−6.15. Turcotte E., Wiens L.W., Grierson J.R. et al. Toxicology evaluation of radiotracer doses of 3'‑deoxy‑3'-[18F]fluorothymidine (18F‑FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med2007;7:3.Turcotte E., Wiens L.W., Grierson J.R. et al. Toxicology evaluation of radiotracer doses of 3'‑deoxy‑3'-[18F]fluorothymidine (18F‑FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med2007;7:3.16. Spence A.M., Muzi M., Link J.M. et al. NCI‑sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Mol Imaging Biol 2008;10:271−80.Spence A.M., Muzi M., Link J.M. et al. NCI‑sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies. Mol Imaging Biol 2008;10:271−80.17. Buck A.K., Bommer M., Stilgenbauer S. et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006; 66:11055−61.Buck A.K., Bommer M., Stilgenbauer S. et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006; 66:11055−61.18. Buck A.K., Halter G., Schirrmeister H. et al. Imaging proliferation in lung tumors with PET: 18F‑FLT versus 18F‑FDG. J Nucl Med 2003;44:1426−31.Buck A.K., Halter G., Schirrmeister H. et al. Imaging proliferation in lung tumors with PET: 18F‑FLT versus 18F‑FDG. J Nucl Med 2003;44:1426−31.19. Eckel F., Herrmann K., Schmidt S. et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F‑fluorothymidine. J Nucl Med 2009;50:1441−7.Eckel F., Herrmann K., Schmidt S. et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F‑fluorothymidine. J Nucl Med 2009;50:1441−7.20. Herrmann K., Wieder H.A., Buck A.K. et al. Early response assessment using 3'‑deoxy-3'‑[18F]fluorothymidine-positron emission tomography in high‑grade non‑Hodgkin's lymphoma. Clin Cancer Res 2007;13:3552−8.Herrmann K., Wieder H.A., Buck A.K. et al. Early response assessment using 3'‑deoxy-3'‑[18F]fluorothymidine-positron emission tomography in high‑grade non‑Hodgkin's lymphoma. Clin Cancer Res 2007;13:3552−8.21. Kenny L.M., Vigushin D.M., Al‑Nahhas A. et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F] fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104−12. 22. Pio B.S., Park C.K., Pietras R. et al. Usefulness of 3'‑[F18]fluoro-3'‑deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8:36−42.Kenny L.M., Vigushin D.M., Al‑Nahhas A. et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F] fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104−12. 22. Pio B.S., Park C.K., Pietras R. et al. Usefulness of 3'‑[F18]fluoro-3'‑deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8:36−42.23. Herrmann K., Buck A.K., Schuster T. et al. A pilot study to evaluate 3'‑deoxy- 3'‑18F‑fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med 2011;52:1898−902.Herrmann K., Buck A.K., Schuster T. et al. A pilot study to evaluate 3'‑deoxy- 3'‑18F‑fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. J Nucl Med 2011;52:1898−902.24. Machulla H.J., Blocher A., Kuntzsch M. et al. Simplified labeling approach for synthesizing 3'‑deoxy-3'‑[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000;243:843−6.Machulla H.J., Blocher A., Kuntzsch M. et al. Simplified labeling approach for synthesizing 3'‑deoxy-3'‑[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000;243:843−6.25. Meignan M., Gallamini A., Meignan M. et al. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009; 50:1257−60.Meignan M., Gallamini A., Meignan M. et al. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009; 50:1257−60.26. Cheson B.D., Horning S.J., Coiffier B. et al. Report of an international workshop to standardize response criteria for non‑Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.Cheson B.D., Horning S.J., Coiffier B. et al. Report of an international workshop to standardize response criteria for non‑Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.27. Terasawa T., Lau J., Bardet S. et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B‑cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906−14.Terasawa T., Lau J., Bardet S. et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B‑cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906−14.28. Kostakoglu L., Goldsmith S.J., Leonard J.P. et al. FDG‑PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107:2678−87.Kostakoglu L., Goldsmith S.J., Leonard J.P. et al. FDG‑PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107:2678−87.